文献速递MDS 与骨髓增殖性肿瘤

慢性粒单核细胞白血病的诊断与管理

Chronic myelomonocytic leukemia diagnosis and management.
PubMed 文献 · Leukemia · 2021-03-13

慢性粒单核细胞白血病(CMML)是一种罕见的异质性髓系恶性肿瘤,被WHO归类为MDS/MPN重叠综合征。持续单核细胞增多是其标志,但诊断具有挑战性。对单核细胞亚群、染色体异常和体细胞基因突变的深入理解提高了诊断和预后分层的准确性。多种风险分层系统已被开发并验证,但优选纳入分子信息的系统如CPSS-Mol、Mayo Molecular和GFM。症状导向的治疗是CMML管理的基础。

要点

  • CMML诊断需结合持续单核细胞增多、骨髓形态及分子遗传学特征。
  • 预后分层推荐使用纳入分子信息的CPSS-Mol、Mayo Molecular或GFM系统。
  • 低危有症状患者可用HMA或减瘤治疗,中高危应考虑异基因造血干细胞移植。

核心结论

  • CMML诊断需综合单核细胞亚群、染色体和基因突变信息,预后分层优选分子整合系统,治疗以症状导向为主,中高危考虑移植。

研究设计与样本

  • 本文为综述,基于PubMed来源文献总结CMML诊断与管理进展。

主要发现

  • 高达20%的CMML患者合并炎症或自身免疫性疾病。
  • 持续单核细胞增多是CMML的标志,但诊断具有挑战性。
  • 多种风险分层系统已开发并验证,优选CPSS-Mol、Mayo Molecular和GFM。

关键数值与推荐

  • 低危但有血细胞减少症状或脾肿大等增殖特征的患者,可分别接受HMA或减瘤治疗以持久控制症状。
  • 中高危患者应考虑异基因造血干细胞移植。
  • 早期临床试验结果有前景,但缺乏有效药物选择。

临床怎么用

  • 对疑似CMML患者,应整合形态学、单核细胞亚群、染色体和分子检测以明确诊断和预后。
  • 采用CPSS-Mol、Mayo Molecular或GFM等分子整合预后系统进行风险分层。
  • 低危有症状者按血细胞减少或增殖特征选用HMA或减瘤治疗;中高危评估异基因移植。

局限性

  • 本文为综述,未报告原始研究数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Chronic myelomonocytic leukemia (CMML) is a rare, heterogeneous myeloid malignancy classified as a myelodysplastic syndromes/myeloproliferative neoplasm (MDS/MPN) overlap syndrome by the World Health Organization (WHO). Its initial presentation can be incidental or associated with myelodysplastic or myeloproliferative symptoms and up to 20% of patients harbor a concurrent inflammatory or autoimmune condition. Persistent monocytosis is the hallmark of CMML but diagnosis can be challenging. Increased understanding of human monocyte subsets, chromosomal abnormalities, and somatic gene mutations have led to more accurate diagnosis and improved prognostication. A number of risk stratification systems have been developed and validated but using those that incorporate molecular information such as CMML Prognostic Scoring System (CPSS)-Mol, Mayo Molecular, and Groupe Francophone des Myelodysplasies (GFM) are preferred. Symptom-directed approaches forms the basis of CMML management. Outcomes vary substantially depending on risk ranging from observation for a number of years to rapidly progressive disease and acute myeloid leukemia (AML) transformation. Patients who are low risk but with symptoms from cytopenias or proliferative features such as splenomegaly may be treated with hypomethylating agents (HMAs) or cytoreductive therapy, respectively, with the goal of durable symptoms control. Allogeneic hematopoietic cell transplantation should be considered for intermediate to high risk patients. The lack of effective pharmaceutical options has generated interest in novel therapeutics for this disease, and early phase clinical trial results are promising.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Chan O, Renneville A, Padron E, et al. Chronic myelomonocytic leukemia diagnosis and management. Leukemia. 2021. PMID: 33714974. doi:10.1038/s41375-021-01207-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。